However, unlike for sodium-glucose co-transporter 2 (SGLT2) inhibitors (McDonagh et al., 2021; Heidenreich et al., 2022)–another novel drug class widely used in type 2 diabetes–a benefit for GLP-1 RAs in HF remains to be fully established in dedicated studies in people with type 2 diabetes as highlighted in some clinical guidelines (Dunlay et al., 2019). This evidence concerns the gene GCG and type 2 diabetes mellitus.